Welcome to our dedicated page for RxSight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
RxSight, Inc. is holding its 2026 Annual Meeting of Stockholders as a fully virtual event on June 16, 2026 at 8:00 a.m. Pacific Time. Holders of 41,396,609 shares of common stock outstanding as of April 21, 2026 are entitled to vote.
Stockholders will vote on electing three Class II directors to terms ending in 2029, an advisory “Say‑on‑Pay” approval of 2025 executive compensation, and ratification of Ernst & Young LLP as independent registered public accounting firm for 2026. The proxy explains voting methods, quorum, broker non-votes, board committee structure, director independence and 2025 non‑employee director compensation, including cash retainers and time‑based RSU awards.
RxSight, Inc. Chief Operating Officer Ilya Goldshleger exercised stock options to acquire 12,489 shares of common stock at $4.13 per share. Following the transactions, he holds 78,180 shares directly and 1,372 shares indirectly through his spouse, indicating a routine compensation-related equity exercise with no open-market buying or selling disclosed.
RxSight Inc disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group no longer beneficially owns those securities. The filing states amount beneficially owned: 0 shares representing 0% of the class.
The amendment explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Ashley Grim, Head of Global Fund Administration.
RxSight, Inc. filed an amended report to update details about the compensation of its new Chief Financial Officer, Mark Wilterding. The company confirms that, under his employment agreement effective January 11, 2026, his cash sign-on bonus was set at $169,348.10 and paid on March 13, 2026, after payroll deductions and required withholding.
The amendment also corrects the vesting schedule for his stock option. 25% of the shares underlying the option will vest on the first anniversary of January 11, 2026, and the remaining shares will vest in equal monthly installments over the following three years, so that all option shares are fully vested four years from that date, subject to his continued employment and the terms of the option agreement. All other aspects of the original report remain unchanged.
RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock. On February 28, 2026, 20,441 restricted stock units were exercised into 20,441 shares of common stock at a price of $0.00 per share. To cover tax obligations on this vesting event, 8,068 shares of common stock were disposed of at $7.61 per share through a tax-withholding arrangement rather than an open-market sale. Footnotes state that one eighth of the RSU award vested on February 28, 2026, with additional one-eighth installments scheduled to vest every six months through the end of a four-year period, subject to continued service.
RxSight, Inc. Chief Customer Officer Scott Gaines reported multiple equity transactions. On February 27, 2026, he received a grant of 32,218 restricted stock units (RSUs), each representing one share of common stock, subject to multi‑year service-based vesting. On February 28, 2026, several RSU awards vested and were exercised, resulting in the acquisition of 6,261 shares of common stock at a stated price of $0.00 per share. On the same date, 2,580 shares of common stock were disposed of at $7.61 per share to cover tax withholding obligations. After these transactions, Gaines directly owned 14,848 shares of RxSight common stock.
Goldshleger Ilya reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units on February 27, 2026. Each RSU represents a right to one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, if he continues as a service provider.
Weinberg Eric reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that officer Eric Weinberg received a grant of 32,218 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, subject to his continued service.
Kurtz Ronald M MD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. President & CEO Ronald M. Kurtz received a grant of 80,545 restricted stock units. Each RSU represents a contingent right to receive one share of RxSight common stock.
The award vests in six equal installments, with one-sixth vesting on the first trading day on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029, as long as he continues as a service provider under the company’s 2021 Equity Incentive Plan.
RxSight, Inc. files Post-Effective Amendment converting its shelf registration to a non-automatic Form S-3 and registers up to $200,000,000 of securities. The amendment converts the registration from a Form S-3ASR to a Form S-3 and updates the shelf to permit offers of common stock, preferred stock, debt securities, warrants and units.
This prospectus is a shelf disclosure providing a general description of the securities and states that specific terms, offering sizes, prices and distribution arrangements will be provided in prospectus supplements; sales may occur from time to time after effectiveness.